| COMPASS PATHWAYS ADR |
| USA |
| Gesundheit |
| US20451W1018 / A2QCDR |
| 5Y6 (Frankfurt) / CMPS (NASDAQ) |
| FRA:5Y6, ETR:5Y6, 5Y6:GR, NASDAQ:CMPS |
| - |
| https://compasspathways.c.. |
|
Compass Pathways plc - ADR is a clinical-stage biotechnology company focused on mental health care. Compass Pathways develops COMP360, a proprietary synthetic psilocybin therapy being studied for treatment-resistant depression and other psychiatric c..
>Volltext.. |
| 1036.4 Mio. EUR |
| 699.03 Mio. EUR |
| - |
| -161.47 Mio. EUR |
| -362.51 Mio. EUR |
| -3.22 EUR |
| 48.61 Mio. EUR |
| 385.98 Mio. EUR |
| -143.07 Mio. EUR |
| 1.18 |
| - |
| -193.82% |
| - |
| - |
| - |
| - |
| COMPASS PATHWAYS |
| 04.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|